Izumi Raquel E.'s Form 4 filing
Vincerx Pharma, Inc. (VINC) · filed Dec 14, 2022
- Accession no.
- 0000899243-22-038530
- Filed
- Dec 14, 2022
- Trade date
- Dec 14, 2022
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $25.3K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Izumi Raquel E.CIK 0001832553 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 14, 2022 | Common Stock | PPurchaseAcquired | +28,738 | $0.88F1 | +$25,289.44 | 68,738 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents a weighted average purchase price. Actual purchase prices ranged from $0.85 to $0.89 per share. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares purchased within the range indicated.
Referenced by the price of 1 transaction in Table I.
Remarks
President and Chief Operations Officer